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Interferon-gamma and interleukin-10 production by
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and neck cancer
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OBJECTIVE: This study aims to evaluate the production of interferon-gamma and interleukin-10 by stimulated
peripheral blood mononuclear cells isolated from patients with supraglottic laryngeal cancer before and after
surgical treatment.
METHODS: Fourteen patients with advanced supraglottic laryngeal cancer were studied. Cultures of peripheral
blood mononuclear cells isolated during the preoperative and late postoperative periods were stimulated with
concanavalin A and Bacille Calmette-Gue ´rin, and the supernatant concentrations of interferon-gamma and
interleukin-10 were measured.
RESULTS: For non-stimulated cultures, the interferon-gamma levels produced by the preoperative period and the
late postoperative period cultures were lower than the levels produced by the control group cultures. The
interferon-gamma levels after stimulation with concanavalin A were higher in the late postoperative period
cultures than in the preoperative evaluation cultures. Stimulation with Bacille Calmette-Gue ´rin led to the
production of similar levels of interferon-gamma and interleukin-10 by all cultures; thus, stimulation increased the
levels of interferon-gamma produced by both the preoperative and postoperative cultures relative to the levels
produced by the corresponding unstimulated cultures.
CONCLUSION: Patients with advanced supraglottic laryngeal cancer exhibit an in vitro deficiency in interferon-
gamma secretion by mononuclear cells. Stimulated cells seem to recover this function during the postoperative
period.
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INTRODUCTION
Although the mechanism of action of Bacille Calmette-
Gue ´rin (BCG) has not been fully elucidated, BCG is
currently regarded as the most successful cancer immu-
notherapy (1). BCG seems to enhance the cellular immune
response in a nonspecific manner by activating macro-
phages and lymphocytes. Intravesical immunotherapy is
clinically well established as a treatment for superficial
bladder cancer, but it remains an experimental treatment for
other solid tumors, such as laryngeal cancer (2).
Cytotoxic CD8
+ T cells play an important role in the
control of tumor cells (3). The immune process, which
culminates in the lysis of tumor cells, often begins with
dendritic cells, which detect the tumor antigens presented
by Major Histocompatibility Complex (MHC) molecules
expressed on tumor cell surfaces and then phagocytose the
presenting cells. These dendritic cells activate lymphocytes,
starting the cytotoxic process and tumor cell lysis. This
entire cell interaction mechanism is coordinated by different
cytokines (4). The proinflammatory activities of cytokines
such as interferon-gamma (IFN-c) are associated with Th1 T
lymphocyte differentiation. IFN-c is thought to be asso-
ciated with anti-tumoral cellular immunity. However,
immune response activation involving cytokines such as
interleukin-10 (IL-10) can promote Th2 T lymphocyte
differentiation and lead to a predominantly humoral
immune response (5).
Although BCG has been used as a successful immu-
notherapy for cancer, few studies have investigated cyto-
kine release by BCG-activated immune cells. In a previous
study, we evaluated the production of TNF-a and IL-6 in the
supernatant of adherent cells cultured from peripheral
blood mononuclear cells (PBMCs) isolated from patients
with supraglottic laryngeal cancer before and after surgical
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587treatment. We found that BCG is able to modulate the
immune response of these patients (6). In this study, we
evaluated the production of IFN-c and IL-10 by cultured
PBMCs isolated from patients with advanced supraglottic
laryngeal cancer. PBMCs were isolated during the pre-
operative period (PREOP) and the late postoperative (LP)
period.
METHODS
Fourteen patients with stage III or IV supraglottic
laryngeal carcinoma were selected at the outpatient clinic
of the University Hospital of the Ribeira ˜o Preto School of
Medicine, Sa ˜o Paulo University. Each tumor was staged
according to the TNM classification. Patients with infectious
and/or inflammatory diseases detected by blood and urine
tests and chest X-rays and patients using immunosuppres-
sive medications were excluded. Surgical treatment con-
sisted of total or partial laryngectomy according to lesion
stage. T3 stage patients underwent total or supraglottic
laryngectomy, and T4 stage patients were treated with
total laryngectomy. Blood samples were collected from all
patients during the PREOP period and at 236¡18 days after
surgery (LP).
Thirteen healthy age- and sex-matched individuals were
recruited as the control group. The presence of neoplasms in
the control volunteers was ruled out by detailed physical
investigation. The study was approved by the Ethics
Committee of the University Hospital of the Ribeira ˜o Preto
School of Medicine, Sa ˜o Paulo University, and all patients
gave written informed consent prior to participation in the
study.
Measurement of the cytokine concentrations
Blood samples were collected from the peripheral vein
under sterile conditions during both the PREOP and LP
periods from patients with laryngeal cancer. Blood staples
were collected only once from the control subjects. Peripheral
blood mononuclear cells (PBMCs) were isolated with a Ficoll-
Hypaque gradient, and their viability was determined by 2%
Trypan Blue exclusion. Cells were kept at a concentration of
2.0x10
5 cells/mL in 12.5% bovine fetal serum. Non-stimu-
lated and stimulated cultures were evaluated; stimulated
cells were exposed to 10 mg/mL of concanavalin A (ConA) or
20 mg/mL of BCG. After 72 h of culture at 37˚C in a humid
environment containing nearly 5% CO2, the supernatant was
collected, and the IL-10 and IFN-c levels were measured (7).
Human monoclonal IL-10 and IFN-c antibodies were
used [Pharmingen International (Life Science Research), San
Diego, CA, USA] as the capture antibodies, and biotinylated
antihuman antibodies against the analyzed cytokines
(Pharmingen) were used as the detecting antibodies.
Binding was detected with peroxidase-labeled streptavidin
(DAKO, Glostrup, Denmark) and O-phenylenediamine-
2HCl/substrate (OPD, Sigma, St. Louis, MO, USA). The
intra-assay and inter-assay variation levels were below 10%.
The detection limits of the cytokine ELISAs were 78 pg/mL
and 39 pg/mL for IFN-c and IL-10, respectively.
The results are reported as the median (M), mean (x) and
standard deviation (SD). GraphPad Prism (San Diego, CA,
USA) was used for statistical analysis. Between-group
comparisons were performed using the Mann-Whitney
and Wilcoxon tests, and p,0.05 was considered statistically
significant.
RESULTS
Demographic data for the patients and controls are shown
in Table 1. All patients smoked an average of 20¡8.5
(x¡DP) cigarettes/day for 44.5¡10 years. Eight patients
received adjuvant radiotherapy 27.1¡8 days after surgery,
and the post-operative evaluation was conducted at least six
months after the completion of the radiotherapy. No patient
exhibited evidence of tumor recurrence at the time of blood
sample collection for LP evaluation, as determined by
endoscopy and radiography. All patients had stopped
smoking by the time of the postoperative evaluation.
Thirteen healthy control subjects were selected, ten men
and three women. The control subjects ranged in age from
40 to 67 years (52¡9.3). No significant differences were
observed between the controls and the patients.
The IFN-c levels in the PREOP and LP BCG-stimulated
cultures were similar to those in the control group cultures,
whereas, the IFN-c levels were lower in the non-stimulated
PREOP and LP cultures than in the non-stimulated control
cultures (Figure 1). For the control cultures, the IFN-c level
was 154.86 (32.32 – 192.8) pg/ml in the non-stimulated
cultures and 239.9 (139.83 – 1,718.08) pg/ml in the BCG-
stimulate cultures. A higher elevation index was observed
in patients at both the PREOP and LP timepoints, with
increases from 27.63 (1.12 – 140.25) pg/ml to 116.19 (5.5 –
3,030.86) pg/ml and from 41.47 (30.03 – 218.09) pg/ml to
186.47 (27.74 – 1,459.73) pg/ml, respectively (Table 2).
The IFN-c levels in the supernatants of non-stimulated
PBMC cultures were lower for the PREOP and LP cultures
than for the control cultures (p=0.001, p=0.04, respectively).
However, when the cultures were stimulated with ConA,
there were no significant differences between the control
cultures and either the PREOP or LP cultures. Higher levels
of IFN-c were observed in the supernatants of the ConA-
stimulated LP cultures than in those of the ConA-stimulated
PREOP cultures (p=0.005) (Figure 1).
The IL-10 levels in the supernatants of the ConA- and
BCG-stimulated cultures of cells from patients in the PREOP
and LP periods were also similar to in the levels for the
control group cultures. The IL-10 level was undetectable in
non-stimulated cultures (Table 2).
DISCUSSION
The impairment of immunological defense mechanisms
may play an important role in cancer pathogenesis.
Decreased in vitro lymphocytic function, lower numbers
and percentages of lymphocytes and impaired lymphopro-
liferation have been reported in many cancer studies (8-12).
Many researchers have examined different aspects of the
immune behavior of head and neck cancer; however, few
studies have examined supraglottic laryngeal cancer speci-
fically. This attention is justified by the local behavior,
Table 1 - Sex, age and tumor stage (TNM classification;
American Joint Committee on Cancer) of the patients and
controls.
Patients Control Group
Sex 12M:2F 10M:3F
Age (years) 58.5 (SD=9) 52 (SD=9.3)
Stage (TNM) 7 stage III/ 7 stage IV -
M: male, F: female, SD: Standard Deviation.
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588regional dissemination capability and potential participa-
tion of the immune system in cancer prognosis in this type
of cancer (13).
IFN-c is the first detectable cytokine at the immunization
site after stimulation with protein antigen and plays a
critical role in the activation and regulation of the immune
response (14). It is a Th1-specific cytokine and promotes the
Th1 response and inhibits the Th2 response. Moreover, IFN-
c activates macrophages, leading to the increased produc-
tion of pro-inflammatory cytokines, including TNF-a,i n
response to different stimuli.
IFN-c was expressed at lower levels in non-stimulated
patient cultures (PREOP and LP) than in control group
cultures, confirming that the immune system is impaired in
these patients. When the cultures were stimulated with
ConA, the secretion of this cytokine was improved, and the
increase was greater in the LP group than in the PREOP
group. The higher levels of IFN-c secretion by the LP
cultures than by the PREOP cultures may be associated with
improved nutritional status in the LP period or due to a
reduction in smoking. Although the effects of smoking and
alcohol abuse on supraglottic laryngeal cancer are not fully
clear, some authors have demonstrated that smoking can
affect some cytokines, mainly IL-4 (15).
Lymphocyte cultures from controls and patients with
laryngeal cancer were stimulated with BCG (Table 2). BCG
induced a more effective increase in IFN-c production in
patient cells (4x increase) than in control cells (1.5x increase).
As IFN-c has a potent anti-tumor activity, these data suggest
that BCG should be tested further in vivo.
Kim (16) observed that in vitro, IL-10 inhibited the
destruction of squamous cell carcinoma tumor cells by
peritumoral lymphocytes. IL-10 inhibits macrophage differ-
entiation and, moreover, inhibits antigen presentation to CD8
T lymphocytes, preventing the effective destruction of tumor
cells. Thus, IL-10 acts as a local immunosuppressive factor,
Figure 1 - Control (C), Preoperative (PREOP) and Late Postoperative (LP) IFN-c (pg/ml) levels in the supernatant of non-stimulated
lymphocytes cultures and in cultures stimulated with Con-A and BCG.
Table 2 - Control, preoperative (PREOP), and late postoperative (LP) IL-10 and IFN-c levels in non-stimulated cell cultures
and in cultures stimulated with ConA and BCG.
IFN-c (pg/ml) IL-10 (pg/ml)
Nonstimulated
cultures
ConA
Stimulation
BCG
Stimulation
Nonstimulated
cultures
ConA
Stimulation
BCG
Stimulation
Control 154.86
(32.32-192.8)
23,111.03
(1,577.56-176,197.9)
239.9
(139.83-1,718.08)
ND
1,093.48
(119.42-2,222.62)
78.63
(0.9-314.62)
PREOP 27.63
(1.12-140.25)
8,976.98
(887.49-95,346.54)
116.19
(5.5-3,030.86)
ND
1,318.25
(362.85-6,262.97)
392.73
(17.84-624.13)
LP 41.47
(30.03-218.09)
40,091.64
(4,314.92-157,944.7)
186.47
(27.74-1,459.73)
ND
1,374.09
(739.97-3,714.12)
151.73
(17.38-580.91)
Data are reported as the median and (range). ND – not detectable.
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In this study, the level of IL-10 production by non-adherent
cells was similar to that of the control cells. This result
indicates that the primary activity of IL-10 is not associated
with the cellular response. The true role of IL-10 in the
immunoregulation of cancer remains controversial (19-21).
Although the influence of IFN-c levels on patient
prognosis has not been examined, further studies that
demonstrate the relationship between activity levels and
angiogenic factors (22) and that evaluate other variables that
can alter the capacity of the immune system, such as alcohol
consumption, poor nutrition and smoking, may support the
clinical application of BCG in selected patients. Ultimately,
BCG may help modify disease progression in terms of
survival and prognosis parameters.
In conclusion, patients with advanced supraglottic lar-
yngeal cancer exhibited an in vitro deficiency in IFN-c
secretion by mononuclear cells. Stimulated cells seem to
recover this function in the postoperative period.
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